Richard A. Schnizer

Array ( [id] => 12466104 [patent_doc_number] => 09987275 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-05 [patent_title] => Targeting PARP1 for treatment of TSC and cancers [patent_app_type] => utility [patent_app_number] => 15/305883 [patent_app_country] => US [patent_app_date] => 2015-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 18991 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15305883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443522 [patent_doc_number] => 20170044540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'SARNA COMPOSITIONS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/305910 [patent_app_country] => US [patent_app_date] => 2015-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 106382 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15305910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11715153 [patent_doc_number] => 20170183652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY' [patent_app_type] => utility [patent_app_number] => 15/305976 [patent_app_country] => US [patent_app_date] => 2015-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 20323 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15305976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12942379 [patent_doc_number] => 09833416 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-05 [patent_title] => Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same [patent_app_type] => utility [patent_app_number] => 14/678589 [patent_app_country] => US [patent_app_date] => 2015-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 60 [patent_no_of_words] => 18634 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14678589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11627630 [patent_doc_number] => 20170137818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'APTAMER INHIBITING BIOLOGICAL ACTIVITY OF AUTOTAXIN BY BINDING WITH AUTOTAXIN, AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/129608 [patent_app_country] => US [patent_app_date] => 2015-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 22015 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15129608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10382196 [patent_doc_number] => 20150267203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'RNA SILENCING IN ANIMALS AS AN ANTIVIRAL DEFENSE' [patent_app_type] => utility [patent_app_number] => 14/668811 [patent_app_country] => US [patent_app_date] => 2015-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12920 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14668811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163693 [patent_doc_number] => 10487328 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Blocking Hepatitis C Virus infection associated liver tumor development with HCV-specific antisense RNA [patent_app_type] => utility [patent_app_number] => 15/129043 [patent_app_country] => US [patent_app_date] => 2015-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 24 [patent_no_of_words] => 17609 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15129043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14885513 [patent_doc_number] => 10422792 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Binding detection using liquid crystal [patent_app_type] => utility [patent_app_number] => 15/121750 [patent_app_country] => US [patent_app_date] => 2015-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 15485 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15121750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11492863 [patent_doc_number] => 20170067048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'ANTISENSE NUCLEIC ACIDS' [patent_app_type] => utility [patent_app_number] => 15/122435 [patent_app_country] => US [patent_app_date] => 2015-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 12205 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15122435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10381981 [patent_doc_number] => 20150266989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'GRAFT POLYMERS FOR ENHANCED INTRACELLULAR DELIVERY OF ANTISENSE MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/629013 [patent_app_country] => US [patent_app_date] => 2015-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 11360 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14629013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10381981 [patent_doc_number] => 20150266989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'GRAFT POLYMERS FOR ENHANCED INTRACELLULAR DELIVERY OF ANTISENSE MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/629013 [patent_app_country] => US [patent_app_date] => 2015-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 11360 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14629013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14172211 [patent_doc_number] => 10260105 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => MiR-320e and colorectal cancer [patent_app_type] => utility [patent_app_number] => 15/120052 [patent_app_country] => US [patent_app_date] => 2015-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 17163 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15120052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11390470 [patent_doc_number] => 09551709 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-24 [patent_title] => 'Universal nucleic acid aptamers for commonly binding to various types of microorganisms and method of producing the same' [patent_app_type] => utility [patent_app_number] => 14/623082 [patent_app_country] => US [patent_app_date] => 2015-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 6921 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14623082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11915625 [patent_doc_number] => 09783803 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-10 [patent_title] => 'Inhibition of NEAT1 for treatment of solid tumors' [patent_app_type] => utility [patent_app_number] => 15/116184 [patent_app_country] => US [patent_app_date] => 2015-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 38 [patent_no_of_words] => 10549 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15116184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943541 [patent_doc_number] => 20170247692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/114277 [patent_app_country] => US [patent_app_date] => 2015-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10256 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15114277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936746 [patent_doc_number] => 20170240896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Inhibitory Oligonucleotides for Treating Tumors' [patent_app_type] => utility [patent_app_number] => 15/115095 [patent_app_country] => US [patent_app_date] => 2015-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 19313 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15115095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12724492 [patent_doc_number] => 20180133331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => Site-Specific DNA-Doxorubicin Conjugates Display Enhanced Cytotoxicity to Breast Cancer Cells [patent_app_type] => utility [patent_app_number] => 15/116915 [patent_app_country] => US [patent_app_date] => 2015-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15116915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10326004 [patent_doc_number] => 20150211009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'MICRORNA-198 AS A TUMOR SUPPRESSOR IN PANCREATIC CANCER' [patent_app_type] => utility [patent_app_number] => 14/615168 [patent_app_country] => US [patent_app_date] => 2015-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 30538 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14615168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11323770 [patent_doc_number] => 20160354382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => 'GAMMA-SECRETASE INHIBITION REDUCE APOC3 LEVELS AND PLASMA TRIGLYCERIDES' [patent_app_type] => utility [patent_app_number] => 15/117155 [patent_app_country] => US [patent_app_date] => 2015-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 12471 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15117155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11402024 [patent_doc_number] => 20170022562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'Biomarkers and Therapeutic Targets for Abnormal Retinal Pigment Epithelium' [patent_app_type] => utility [patent_app_number] => 15/113444 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13937 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15113444 [rel_patent_id] =>[rel_patent_doc_number] =>)